腰围
肥胖
超重
减肥
医学
不利影响
内分泌学
内科学
胰高血糖素
兴奋剂
胰高血糖素样肽-1
激素
糖尿病
受体
2型糖尿病
作者
Maryam Deravi,Chris Piszczatoski,Bradley Phillips,Jessica Reid,Angelina Vascimini
标识
DOI:10.1177/87551225241285326
摘要
Retatrutide, a hormone receptor agonist targeting glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide, is being developed to treat obesity. A literature review from April 2019 to April 2024 included such terms as "retatrutide," "LY3437943," "overweight," and "obesity." Phase I proof-of-concept studies led to phase II trials showing up to 24% body weight reduction and nearly 20 cm waist circumference reduction. The most common adverse effects were gastrointestinal. Ongoing phase II and III studies aim to further evaluate the safety and efficacy of retatrutide as a novel triagonist for obesity treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI